# Heesun Joyce Rogers

## List of Publications by Citations



| | | | |
|---|---|---|---|
| 59 papers | 913 citations | 15 h-index | 30 g-index |
| 65 ext. papers | 1,178 ext. citations | 4.4 avg, IF | 4.51 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 59 | SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes. *Blood*, **2012**, 120, 3173-86 | 2.2 | 152 |
| 58 | Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms. *Blood*, **2014**, 123, 2645-51 | 2.2 | 145 |
| 57 | COVID-19 and the clinical hematology laboratory. *International Journal of Laboratory Hematology*, **2020**, 42 Suppl 1, 11-18 | 2.5 | 119 |
| 56 | Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specified. *Modern Pathology*, **2016**, 29, 854-64 | 9.8 | 74 |
| 55 | Hypercoagulable states: an algorithmic approach to laboratory testing and update on monitoring of direct oral anticoagulants. *Blood Research*, **2014**, 49, 85-94 | 1.4 | 51 |
| 54 | Pathogenesis of myelodysplastic syndromes: an overview of molecular and non-molecular aspects of the disease. *Blood Research*, **2014**, 49, 216-27 | 1.4 | 38 |
| 53 | Bone marrow morphology is a strong discriminator between chronic eosinophilic leukemia, not otherwise specified and reactive idiopathic hypereosinophilic syndrome. *Haematologica*, **2017**, 102, 1352-1360 | 6.6 | 37 |
| 52 | Oligomonocytic chronic myelomonocytic leukemia (chronic myelomonocytic leukemia without absolute monocytosis) displays a similar clinicopathologic and mutational profile to classical chronic myelomonocytic leukemia. *Modern Pathology*, **2017**, 30, 1213-1222 | 9.8 | 36 |
| 51 | Mutations in Splicing Factor Genes in Myeloid Malignancies: Significance and Impact on Clinical Features. *Cancers*, **2019**, 11, | 6.6 | 33 |
| 50 | Hematopoietic neoplasms with 9p24/JAK2 rearrangement: a multicenter study. *Modern Pathology*, **2019**, 32, 490-498 | 9.8 | 30 |
| 49 | Myeloproliferative neoplasms with concurrent BCR-ABL1 translocation and JAK2 V617F mutation: a multi-institutional study from the bone marrow pathology group. *Modern Pathology*, **2018**, 31, 690-704 | 9.8 | 22 |
| 48 | Severe megaloblastic anemia: Vitamin deficiency and other causes. *Cleveland Clinic Journal of Medicine*, **2020**, 87, 153-164 | 2.8 | 18 |
| 47 | Splicing factor 3b subunit 1 (Sf3b1) haploinsufficient mice display features of low risk Myelodysplastic syndromes with ring sideroblasts. *Journal of Hematology and Oncology*, **2014**, 7, 89 | 22.4 | 16 |
| 46 | Comparison of therapy-related and de novo core binding factor acute myeloid leukemia: A bone marrow pathology group study. *American Journal of Hematology*, **2020**, 95, 799-808 | 7.1 | 15 |
| 45 | JAK2 V617F-positive acute myeloid leukaemia (AML): a comparison between de novo AML and secondary AML transformed from an underlying myeloproliferative neoplasm. A study from the Bone Marrow Pathology Group. *British Journal of Haematology*, **2018**, 182, 78-85 | 4.5 | 15 |
| 44 | Clinical, immunophenotypic, and genomic findings of acute undifferentiated leukemia and comparison to acute myeloid leukemia with minimal differentiation: a study from the bone marrow pathology group. *Modern Pathology*, **2019**, 32, 1373-1385 | 9.8 | 14 |
| 43 | Vacuolization of hematopoietic precursors: an enigma with multiple etiologies. *Blood*, **2021**, 137, 3685-3689 | 22.1 | 12 |

| | | | |
|---|---|---|---|
| 42 | Clinicopathologic and molecular characterization of myeloid neoplasms harboring isochromosome 17(q10). *American Journal of Hematology*, **2014**, 89, 862 | 7.1 | 9 |
| 41 | Frequency, interobserver reproducibility and clinical significance of equivocal peaks in PCR clonality testing using Euroclonality/BIOMED-2 primers. *Journal of Clinical Pathology*, **2014**, 67, 1093-8 | 3.9 | 8 |
| 40 | Concordance among hematopathologists in classifying blasts plus promonocytes: A bone marrow pathology group study. *International Journal of Laboratory Hematology*, **2020**, 42, 418-422 | 2.5 | 8 |
| 39 | Molecular and phenotypic heterogeneity of refractory anemia with ring sideroblasts associated with marked thrombocytosis. *Leukemia and Lymphoma*, **2016**, 57, 212-5 | 1.9 | 6 |
| 38 | Thrombotic thrombocytopenic purpura: The role of ADAMTS13. *Cleveland Clinic Journal of Medicine* , **2016**, 83, 597-603 | 2.8 | 6 |
| 37 | Most Myeloid Neoplasms With Deletion of Chromosome 16q Are Distinct From Acute Myeloid Leukemia With Inv(16)(p13.1q22): A Bone Marrow Pathology Group Multicenter Study. *American Journal of Clinical Pathology*, **2017**, 147, 411-419 | 1.9 | 5 |
| 36 | Myeloid/lymphoid neoplasms with FLT3 rearrangement. *Modern Pathology*, **2021**, 34, 1673-1685 | 9.8 | 5 |
| 35 | Chronic myeloid neoplasms harboring concomitant mutations in myeloproliferative neoplasm driver genes (JAK2/MPL/CALR) and SF3B1. *Modern Pathology*, **2021**, 34, 20-31 | 9.8 | 5 |
| 34 | Acute parvovirus B19 infection detected in bone marrow biopsy. *Blood*, **2015**, 126, 1630 | 2.2 | 4 |
| 33 | The hematology laboratory's response to the COVID-19 pandemic: A scoping review. *International Journal of Laboratory Hematology*, **2021**, 43, 148-159 | 2.5 | 4 |
| 32 | A reevaluation of erythroid predominance in Acute Myeloid Leukemia using the updated WHO 2016 Criteria. *Modern Pathology*, **2018**, 31, 873-880 | 9.8 | 3 |
| 31 | Aberrant activation-induced cytidine deaminase expression in Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia. *Human Pathology*, **2016**, 52, 173-8 | 3.7 | 3 |
| 30 | Very rare lineage switch from acute myeloid leukemia to mixed phenotype acute leukemia, B/Myeloid, during chemotherapy with no clonal evolution. *International Journal of Laboratory Hematology*, **2019**, 41, e86-e88 | 2.5 | 2 |
| 29 | Very unusual expression of multiple aberrant T-cell markers in plasmablastic plasma cell myeloma. *International Journal of Laboratory Hematology*, **2019**, 41, e89-e91 | 2.5 | 2 |
| 28 | Myeloid Neoplasms with inv(3)(q21q26.2) or t(3;3)(q21;q26.2). *Surgical Pathology Clinics*, **2013**, 6, 677-92 | 3.9 | 2 |
| 27 | Genetic and Epigenetic Defects in the Autophagy Machinery in Myelodysplastic Syndromes. *Blood*, **2016**, 128, 4301-4301 | 2.2 | 2 |
| 26 | Myeloid neoplasm with eosinophilia and fusion. *Leukemia and Lymphoma*, **2020**, 61, 213-216 | 1.9 | 2 |
| 25 | Analysis of distinct hotspot mutations in relation to clinical phenotypes and response to therapy in myeloid neoplasia. *Leukemia and Lymphoma*, **2021**, 62, 735-738 | 1.9 | 2 |

| | | | |
|---|---|---|---|
| 24 | Acute myeloid leukemia with inv(16)(p13.1q22), abnormal eosinophils, and absence of peripheral blood and bone marrow blasts. *American Journal of Hematology*, **2016**, 91, E273-4 | 7.1 | 1 |
| 23 | What Is the Clinical Utility of Repeat SNP Array Testing in the Follow-up of Myeloid Neoplasms?: A Retrospective Analysis of 44 Patients With Serial SNP Arrays. *American Journal of Clinical Pathology*, **2017**, 147, 278-284 | 1.9 | 1 |
| 22 | Somatic Mutations in Splicing Factor 3b, Subunit 1 (SF3B1) Are a Useful Biomarker to Differentiate Between Clonal and Non-Clonal Causes of Sideroblastic Anemia. *Blood*, **2014**, 124, 5597-5597 | 2.2 | 1 |
| 21 | Elevated Basal Autophagy in SF3B1 Mutated Myelodysplastic Syndromes: Relationship with Survival Outcomes and Therapeutic Implications. *Blood*, **2015**, 126, 1647-1647 | 2.2 | 1 |
| 20 | A History of Abnormal Bleeding Correlates with Platelet Dysfunction in Aggregation Studies but Not PFA-100 Analyses. *Blood*, **2015**, 126, 3447-3447 | 2.2 | 1 |
| 19 | Burden of Disease and Clinical Responses in Low and Intermediate-1 Risk Myelofibrosis Patients Treated with Ruxolitinib. *Blood*, **2014**, 124, 1834-1834 | 2.2 | 1 |
| 18 | Targeting Autophagy in Myelodysplastic Syndromes. *Blood*, **2016**, 128, 4295-4295 | 2.2 | 1 |
| 17 | Monoclonal IgM gammopathy in adult acquired pure red cell aplasia: culprit or innocent bystander?. *Blood Cells, Molecules, and Diseases*, **2021**, 91, 102595 | 2.1 | 1 |
| 16 | Clonal trajectories and cellular dynamics of myeloid neoplasms with SF3B1 mutations. *Leukemia*, **2021**, 35, 3324-3328 | 10.7 | 0 |
| 15 | Cyclosporine dependent pure red cell aplasia: a case presentation. *Blood Cells, Molecules, and Diseases*, **2015**, 54, 281-3 | 2.1 | |
| 14 | Very rare Burkitt lymphoma with plasmacytoid differentiation, initial presentation as a CNS tumor, and poor prognosis. *International Journal of Laboratory Hematology*, **2021**, | 2.5 | |
| 13 | Lymphocyte Cytosolic Protein 1 I232F Mutation Impairs Granulocytic Proliferation with a G2/M Block in Severe Neutropenia. *Blood*, **2021**, 138, 434-434 | 2.2 | |
| 12 | Molecular Derivation of Extramedullary Myeloid Sarcomas Based on Machine Learning Analysis of Genomic Clusters in AML. *Blood*, **2021**, 138, 1295-1295 | 2.2 | |
| 11 | Somatic Mutations in the Wiskott-Aldrich Syndrome Protein Family Member 3 (WASF3) Are Associated with Poor Prognosis in Myeloid Malignancies. *Blood*, **2014**, 124, 4600-4600 | 2.2 | |
| 10 | Impact of Non-JAK2 Molecular Mutations and Cryptic SNP Lesions in Myelofibrosis Patients Treated with Ruxolitinib. *Blood*, **2014**, 124, 3194-3194 | 2.2 | |
| 9 | Somatic Mutations of the Breast Cancer Amplified Sequence-1 (BCAS1), a Novel Leukemogenic Driver in Myelodysplastic Syndromes with Del(20q). *Blood*, **2014**, 124, 3250-3250 | 2.2 | |
| 8 | Nitric Oxide As a Mediator of Bone Marrow Fibrosis in Patients with Myelofibrosis. *Blood*, **2014**, 124, 4587-4587 | 2.2 | |
| 7 | Risk of Arterial and Venous Thrombosis in Patients with Indeterminate Lupus Anticoagulant Testing. *Blood*, **2014**, 124, 4249-4249 | 2.2 | |

# List of Publications

| | | |
|---|---|---|
| 6 | Post Operative Thrombosis Among Patients Testing Indeterminate for Lupus Anticoagulant. *Blood*, **2014**, 124, 4255-4255 | 2.2 |
| 5 | Platelet Function Testing Is Commonly Performed in Patients with Known Confounding Factors. *Blood*, **2015**, 126, 4726-4726 | 2.2 |
| 4 | Suboptimal Antiplatelet Therapy Suggested By Platelet Aggregation Studies Does Not Correlate with a Change in Clinical Management. *Blood*, **2015**, 126, 4634-4634 | 2.2 |
| 3 | Diastolic but Not Systolic Heart Failure Is Associated with Multiple Abnormalities on Platelet Aggregation Testing. *Blood*, **2015**, 126, 1079-1079 | 2.2 |
| 2 | Recombinant β-Glycoprotein I (βGPI) Produced Using a Novel Lentiviral Approach Functions at Least As Well As Plasma-Derived βGPI in Detection of Anti-βGPI Antibodies. *Blood*, **2016**, 128, 2596-2596 | 2.2 |
| 1 | The first concurrent diagnosis of acute symptomatic Babesiosis and chronic myeloid leukemia in a healthy young adult. *Blood Research*, **2018**, 53, 163-166 | 1.4 |